[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499883":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":37,"centralContacts":41,"locations":46,"responsibleParty":62,"collaborators":11,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":11,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":11,"enrollmentInfo":73,"targetDuration":11,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":11,"overallStatus":49,"whyStopped":11,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Three-drug arm","EXPERIMENTAL",null,[13],"Drug: camrelizumab+apatinib+TMZ",{"label":15,"type":16,"description":11,"interventionNames":17},"Two-drug arm","ACTIVE_COMPARATOR",[18],"Drug: camrelizumab+apatinib",{"label":20,"type":16,"description":11,"interventionNames":21},"single-drug arm",[22],"Drug: camrelizumab",[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","camrelizumab+apatinib+TMZ","camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg\u002Fm2，day1-5\u002F28",[9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"camrelizumab+apatinib","camrelizumab 200mg，q2w+apatinib 250mg qd",[15],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"camrelizumab","camrelizumab 200mg，q2w",[20],[38],{"name":39,"affiliation":5,"role":40},"Jun Guo, Dr","PRINCIPAL_INVESTIGATOR",[42],{"name":39,"role":43,"phone":44,"phoneExt":11,"email":45},"CONTACT","010-88121122","guoj307@126.com",[47],{"facility":48,"status":49,"city":50,"state":11,"zip":11,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Beijing Cancer Hospital","RECRUITING","Beijing","China","CN",{"type":54,"coordinates":55},"Point",[56,57],116.39723,39.9075,{"lat":57,"lon":56},[60],{"name":61,"role":43,"phone":11,"phoneExt":11,"email":45},"Jun Guo",{"type":40,"investigatorFullName":61,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Chief physician","100499883","phase-3-camrelizumab-in-combination-with-apatinib-and-temozolomide-as-first-line-treatment-in-advanced-acral-melanoma-100499883",false,"NCT05789043","Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma","Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma: a Multicenter, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* age:≥18 years, male or female.\n* Histopathologically confirmed recurrence, inoperable resection or metastatic acral melanoma (stage III\u002FIV).\n* Has not received any systematic anti-tumor drug treatment.\n* Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.\n* ECOG 0-1.\n* Adequate organ function.\n* Life expectancy of greater than 12 weeks.\n* Patient has given written informed consent.\n\nExclusion Criteria:\n\n* Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy.\n* Known history of hypersensitivity to macromolecular protein preparation or any components of the drug formulation.\n* Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ);\n* Subjects with any active autoimmune disease or history of autoimmune disease Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \\> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;\n* Received a live vaccine within 4 weeks before the first dose of study medication.\n* Pregnancy or breast feeding.\n* Decision of unsuitableness by principal investigator or physician-in charge.","ALL","18 Years",{"count":74,"type":75},140,"ESTIMATED","INTERVENTIONAL",[78],"PHASE3","It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.",[81],"Acral Melanoma","2023-09-04",{"date":84,"type":85},"2023-09-06","ACTUAL",{"date":87,"type":85},"2023-03-21",{"date":89,"type":75},"2027-02-15",{"name":5,"class":6},1]